Krka, d. d. (FRA:KN8)

Market Cap	7.92B +30.6%
Revenue (ttm)	2.11B +7.1%
Net Income	417.65M +9.6%
EPS	13.75 +10.6%
Shares Out	n/a
PE Ratio	18.96
Forward PE	18.09
Dividend	9.10 (3.45%)
Ex-Dividend Date	Jul 21, 2026

Volume	n/a
Open	257.00
Previous Close	253.50
Day's Range	257.00 - 258.00
52-Week Range	184.00 - 300.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabo...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 13,300
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KN8

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error